MXPA02001343A - Derivados de 6-azauracilo que inhiben interleucina-5. - Google Patents

Derivados de 6-azauracilo que inhiben interleucina-5.

Info

Publication number
MXPA02001343A
MXPA02001343A MXPA02001343A MXPA02001343A MXPA02001343A MX PA02001343 A MXPA02001343 A MX PA02001343A MX PA02001343 A MXPA02001343 A MX PA02001343A MX PA02001343 A MXPA02001343 A MX PA02001343A MX PA02001343 A MXPA02001343 A MX PA02001343A
Authority
MX
Mexico
Prior art keywords
derivatives
inhibiting
interleukin
azauracil
processes
Prior art date
Application number
MXPA02001343A
Other languages
English (en)
Inventor
Eddy Jean Edgard Freyne
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MXPA02001343A publication Critical patent/MXPA02001343A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0491Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0461Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0463Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0468Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invencion se refiere a derivaos de 6-azauracilo que inhiben IL-5 de la formula (1) utiles para tratar enfermedades inflamatorias que dependen de eosinofilos, a procesos e intermediarios para su preparacion asi como a composiciones farmaceuticas que comprenden dichos derivados; ademas se refiere al uso de dichos derivados como una medicina, y a procesos para marcar un receptor o representar la imagen de un organo usando dichos derivados.
MXPA02001343A 1999-08-06 2000-07-31 Derivados de 6-azauracilo que inhiben interleucina-5. MXPA02001343A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99870170 1999-08-06
EP99126035 1999-12-27
PCT/EP2000/007358 WO2001010866A1 (en) 1999-08-06 2000-07-31 Interleukin-5 inhibiting 6-azauracil derivatives

Publications (1)

Publication Number Publication Date
MXPA02001343A true MXPA02001343A (es) 2002-07-22

Family

ID=26153219

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02001343A MXPA02001343A (es) 1999-08-06 2000-07-31 Derivados de 6-azauracilo que inhiben interleucina-5.

Country Status (30)

Country Link
US (1) US6911444B2 (es)
EP (1) EP1206471B1 (es)
JP (1) JP2003506451A (es)
KR (1) KR100795484B1 (es)
CN (1) CN1188410C (es)
AR (1) AR025046A1 (es)
AT (1) ATE318811T1 (es)
AU (1) AU780047B2 (es)
BG (1) BG106367A (es)
BR (1) BR0013014A (es)
CA (1) CA2380759A1 (es)
CO (1) CO5050264A1 (es)
CZ (1) CZ2002356A3 (es)
DE (1) DE60026312T2 (es)
EA (1) EA004740B1 (es)
EE (1) EE200200057A (es)
ES (1) ES2260031T3 (es)
HK (1) HK1048634B (es)
HR (1) HRP20020096A2 (es)
HU (1) HUP0202692A3 (es)
IL (1) IL147976A0 (es)
MX (1) MXPA02001343A (es)
MY (1) MY133512A (es)
NO (1) NO322386B1 (es)
NZ (1) NZ516506A (es)
PL (1) PL353475A1 (es)
SK (1) SK1642002A3 (es)
TR (1) TR200200310T2 (es)
TW (1) TWI271404B (es)
WO (1) WO2001010866A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
WO2003072554A1 (en) * 2002-02-28 2003-09-04 Takeda Chemical Industries, Ltd. Azole compounds
EP1758874A1 (en) * 2004-05-29 2007-03-07 7TM Pharma A/S Substituted thiazoleacetic acids as crth2 ligands
EP2331541B1 (en) 2008-09-04 2015-04-22 Boehringer Ingelheim International GmbH Indolizine inhibitors of leukotriene production
JP4743340B1 (ja) * 2009-10-28 2011-08-10 セントラル硝子株式会社 保護膜形成用薬液
US8420655B2 (en) 2009-12-04 2013-04-16 Boehringer Ingelheim International Gmbh Benzimidazole inhibitors of leukotriene production
EA201300250A1 (ru) 2010-08-16 2013-08-30 Бёрингер Ингельхайм Интернациональ Гмбх Оксадиазольные ингибиторы продуцирования лейкотриена
EP2609092B1 (en) 2010-08-26 2015-04-01 Boehringer Ingelheim International GmbH Oxadiazole inhibitors of leukotriene production
AU2011305667A1 (en) 2010-09-23 2013-03-21 Boehringer Ingelheim International Gmbh Oxadiazole inhibitors of leukotriene production
JP5828188B2 (ja) * 2010-09-23 2015-12-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン産生のオキサジアゾール阻害剤
JP5928958B2 (ja) 2010-10-29 2016-06-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン生成のベンゾイミダゾールインヒビター
WO2012061169A1 (en) 2010-11-01 2012-05-10 Boehringer Ingelheim International Gmbh Benzimidazole inhibitors of leukotriene production
WO2012082817A1 (en) 2010-12-16 2012-06-21 Boehringer Ingelheim International Gmbh Biarylamide inhibitors of leukotriene production
AR089853A1 (es) 2012-02-01 2014-09-24 Boehringer Ingelheim Int Inhibidores de oxadiazol de la produccion de leucotrienos para terapia de combinacion, composicion farmaceutica, uso

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US42416A (en) * 1864-04-19 Improvement in harvesters
US10177A (en) * 1853-11-01 Improved pen and pencil case
FR2476087A1 (fr) * 1980-02-18 1981-08-21 Roussel Uclaf Nouvelles oximes derivees de l'acide 3-alkyloxy ou 3-alkyl-thiomethyl 7-amino thiazolyl acetamido cephalosporanique, leur procede de preparation et leur application comme medicaments
CA1244024A (en) 1984-08-01 1988-11-01 Gustaaf M. Boeckx .alpha.- ARYL-4-(4,5-DIHYDRO-3,5-DIOXO-1,2,4-TRIAZIN- 2(3H)-YL)BENZENEACETONITRILES
US4631278A (en) 1984-08-01 1986-12-23 Janssen Pharmaceutica N.V. Anti-protozoal α-aryl-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3H)-yl)-benzeneacetonitrile derivatives, pharmaceutical compositions, and method of use therefor
GB8602342D0 (en) 1986-01-30 1986-03-05 Janssen Pharmaceutica Nv 5 6-dihydro-2-(substituted phenyl)-1 2 4-triazine-3 5(2h 4h)-diones
TR200000153T2 (tr) * 1997-07-10 2000-07-21 Janssen Pharmaceutica N.V. İl-5 inhibite eden 6-azaurasil türevleri.
CN1261881A (zh) 1997-07-10 2000-08-02 詹森药业有限公司 作为il-5-抑制剂的6-氮杂尿嘧啶衍生物
EP0987265A1 (en) 1998-09-18 2000-03-22 Janssen Pharmaceutica N.V. Interleukin-5 inhibiting 6-azauracil derivatives

Also Published As

Publication number Publication date
AU780047B2 (en) 2005-02-24
HUP0202692A2 (hu) 2002-12-28
TWI271404B (en) 2007-01-21
DE60026312D1 (de) 2006-04-27
JP2003506451A (ja) 2003-02-18
EA200200232A1 (ru) 2002-08-29
EP1206471A1 (en) 2002-05-22
SK1642002A3 (en) 2003-03-04
NZ516506A (en) 2004-02-27
WO2001010866A1 (en) 2001-02-15
NO322386B1 (no) 2006-09-25
HK1048634B (zh) 2005-09-30
EA004740B1 (ru) 2004-08-26
EE200200057A (et) 2003-04-15
BR0013014A (pt) 2002-04-16
AU6160900A (en) 2001-03-05
EP1206471B1 (en) 2006-03-01
IL147976A0 (en) 2002-09-12
ES2260031T3 (es) 2006-11-01
US6911444B2 (en) 2005-06-28
KR100795484B1 (ko) 2008-01-16
CN1368972A (zh) 2002-09-11
DE60026312T2 (de) 2006-12-21
MY133512A (en) 2007-11-30
PL353475A1 (en) 2003-11-17
HK1048634A1 (en) 2003-04-11
TR200200310T2 (tr) 2002-08-21
NO20020565D0 (no) 2002-02-05
HRP20020096A2 (en) 2005-10-31
KR20020012317A (ko) 2002-02-15
HUP0202692A3 (en) 2003-01-28
NO20020565L (no) 2002-03-26
CZ2002356A3 (cs) 2002-06-12
BG106367A (bg) 2002-09-30
CO5050264A1 (es) 2001-06-27
ATE318811T1 (de) 2006-03-15
CA2380759A1 (en) 2001-02-15
US20030114453A1 (en) 2003-06-19
CN1188410C (zh) 2005-02-09
AR025046A1 (es) 2002-11-06

Similar Documents

Publication Publication Date Title
NZ516506A (en) Interleukin-5 inhibiting 6-azauracil derivatives
BR0206955A (pt) Ligantes de receptores de canabinóides
BR0314577A (pt) Derivados de triazol como inibidores do fator de crescimento de transformação (tgf)
JO2503B1 (en) Benzathiazole derivatives
MXPA03005464A (es) Agentes antivirales.
ES2158103T3 (es) Derivados de benzofurano utiles como inhibidores de la resorcion osea.
NO20050838L (no) Nye pyrazolforbindelser som transformerende vekstfaktor (TGF)-inhibitorer
ATE316083T1 (de) Adamantanderivate
HK1094425A1 (en) Substituted 2-aminotetralines for the preventive treatment of parkinson's disease
BRPI0509074A (pt) composições farmacêuticas compreendendo agonistas do receptor da tiróide
DK0894084T3 (da) Kanelsyrederivater og deres anvendelse som integrinantagonister
DE69705300T2 (de) Cyclopropylalkansäurederivate
HK1070054A1 (en) Arylsulfonyl derivatives with5-ht6 receptor affinity
SE0402925D0 (sv) Novel Compounds
SE9804212D0 (sv) Compounds
BR0115424A (pt) Composto, composição farmacêutica, métodos para inibir a liberação de peptìdeo beta-amilóide e/ou sua sìntese, para tratar a doença de alzheimer, para prevenir a doença de alzheimer, e para inibir o progresso da doença de alzheimer, processos para preparar o composto, e para preparar lactamas, e, uso do composto
PT1165544E (pt) 1,4-di-hidroindeno¬1,2-c|pirazoles substituidos como inibidores de tirosina-quinase
TW200519101A (en) Benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors
ATE267816T1 (de) Tan-1057 derivate
IT1307786B1 (it) Analoghi di ceramidi, processo per la loro preparazione e loro usocome antitumorali.
TW200519102A (en) Hydronopol substituted benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors
BRPI0412477A (pt) aperfeiçoados polipeptìdeos de interferon-beta-1b recombinantes humanos
PE20030236A1 (es) Derivados de bencimidazol 1-aril-2-n,s- u o-sustituidos, obtencion de medicamentos y preparados farmaceuticos que contienen estos derivados
BR0113671A (pt) Antagonistas de integrina alfa v beta 3 gem-substituìda
RS20050426A (en) Substituted aralkyl derivatives

Legal Events

Date Code Title Description
FG Grant or registration